Mayne International Pty Patent-Cliff Exposure & CMS Drug Spending Portfolio

Mayne International Pty (US): 2 reconciled FDA prescription therapies, $2.4M 2024 CMS Part D & Medicaid spend, and $1,200 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2033-01-01
2024 CMS Total Public Spend$2.4M
2024 Medicare Part D Spend$803K
2024 Medicaid Spend$1.6M
California HCAI SB 17 FilingsSpecialty launch notice ($1,200 intro WAC)